alexa Angiotensin II antagonists in systolic blood pressure control.
Pharmaceutical Sciences

Pharmaceutical Sciences

Pharmaceutica Analytica Acta

Author(s): McInnes GT

Abstract Share this page

Abstract Control of systolic blood pressure should be the primary goal of treatment as it is increasingly recognized as a major determinant of cardiovascular risk. Better control offers enormous potential benefits. Effective treatment is desirable but difficult to achieve. All antagonists, particularly eprosartan, are likely to have an increasingly important role in management strategies.
This article was published in Hosp Med and referenced in Pharmaceutica Analytica Acta

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version